FomepizoleInjection

The first "AP" Rated preservative free generic to Antizol^®*1
Vial closure is not made with natural rubber latex

	Pack NDC#	Strength	Supplied As	Shelf Pack	Vial Opening Size	Product Info	Availability
	Strength: 1 g/mL Supplied As: 1.5 mL Single Dose Vial NDC#: 0517-0710-01	0517-0710-01	1 g/mL	1.5 mL Single Dose Vial	1	13 mm	Product Label Full Prescribing Information Safety Data Sheet	In Stock
Shelf Pack 1 Availability In Stock Product Label Full Prescribing Information Safety Data Sheet Wholesaler Numbers ABC/SAP 10189121 Cardinal 5468533 McKesson 3926169 Morris & Dickson 387571 Case Information Unit of Sale NDC 0517-0710-01 Order Size 1 Case Size 80 Case Per Tier -- Locate Distributor Receive Availability Emails

*Antizol® is a registered trademark of Paladin Labs Inc.

¹Approved Drug Products with Therapeutic Equivalence Evaluations.
https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=078368. Accessed February 2021.

View Our Sales and Return Policy

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy

P: 800-645-1706
(8:00am–6pm Monday - Thursday and Friday 8:00am–4pm Eastern Time)
P: 800-734-9236
F: 610-650-0170

E: pv@americanregent.com

Adverse Drug Events (ADEs) may be reported to the FDA:
Phone: 1-800-FDA-1088
Web: www.fda.gov/medwatch
P: 888-354-4859

E: pqc@americanregent.com
P: 888-354-4855
(9am–5pm Eastern Time, Monday - Friday)

E: ma@americanregent.com

For drug information outside of normal business hours that cannot wait until the next day, please call:

P: 877-845-6371
American Regent, Inc.
5 Ramsey Road
Shirley, NY 11967

P: 631-924-4000
F: 631-924-1731

Find a Distributor

Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent^® database, please submit a message request to corpcommunications@americanregent.com.

Caution: Must be diluted prior to use. For intravenous use only.

INDICATIONS AND USAGE
Fomepizole Injection is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Fomepizole Injection should not be administered to patients with a documented serious hypersensitivity reaction to Fomepizole Injection or other pyrazoles.

PRECAUTIONS
General: Fomepizole Injection should not be given undiluted or by bolus injection.

Minor allergic reactions have been reported. Patients should be monitored for signs of allergic reactions.

Laboratory Tests: Monitor patient throughout the treatment.

Pregnancy: Pregnancy Category C: Fomepizole should be given to pregnant women only if clearly needed.

Nursing Mothers: Caution should be exercised when fomepizole is administered to a nursing woman.

Pediatric and Geriatric Use: Safety and effectiveness have not been established.

ADVERSE REACTIONS
The most frequent adverse events reported as drug-related or unknown relationship to study drug in those who received Fomepizole Injection were headache (14%), nausea (11%), and dizziness, increased drowsiness, and bad taste/metallic taste (6% each). All other adverse events in this population were reported in approximately 3% or fewer of those receiving fomepizole and were as follows:
Body as a Whole: Abdominal pain, fever, multiorgan system failure, pain during fomepizole injection, inflammation at injection site, lumbalgia/backache, hangover.
Cardiovascular: Sinus bradycardia/bradycardia, phlebosclerosis, tachycardia, phlebitis, shock, hypotension.
Gastrointestinal: Vomiting, diarrhea, dyspepsia, heartburn, decreased appetite, transient transaminitis.
Hemic/Lymphatic: Eosinophilia/hypereosinophilia, lymphangitis, disseminated intravascular coagulation, anemia.
Nervous: Lightheadedness, seizure, agitation, feeling drunk, facial flush, vertigo, nystagmus, anxiety, “felt strange,” decreased environmental awareness.
Respiratory: Hiccups, pharyngitis.
Skin/Appendages: Application site reaction, rash.
Special Senses: Abnormal smell, speech/visual disturbances, transient blurred vision, roar in ear.
Urogenital: Anuria.

USE IN SPECIAL POPULATIONS
Fomepizole Injection has not been studied sufficiently to determine whether the pharmacokinetics differ for geriatric and pediatric populations and between genders.
Renal Insufficiency: The metabolites of fomepizole are excreted renally. Definitive pharmacokinetic studies have not been done to assess pharmacokinetics in patients with renal impairment.
Hepatic Insufficiency: Fomepizole is metabolized through the liver, but no definitive pharmacokinetic studies have been done in subjects with hepatic disease.

OVERDOSAGE
Nausea, dizziness, and vertigo were noted in healthy volunteers receiving 3 to 6 times the recommended dose. This dose-dependent CNS effect was short-lived in most subjects and lasted up to 30 hours in one subject. Fomepizole is dialyzable, and hemodialysis may be useful in treating cases of overdosage.

For additional Safety Information, please see Full Prescribing Information. You are encouraged to report Adverse Drug Events to American Regent Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

_{REF-0838 10/2019}